Related Experiment Video
Updated: Dec 11, 2025
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation
Ye Zhao1, Shikara Keshiya2, Gayathri Perera2
1Neuroscience Research Australia, Sydney NSW 2031 & School of Medical Sciences, Faculty of Medicine, University of New South Wales Australia, Sydney, NSW 2052, Australia; Brain and Mind Centre & Central Clinical School, Faculty of Medicine and Health, University of Sydney, NSW 2006, Australia.
Abstract:
Kinase activating missense mutations in leucine-rich repeat kinase 2 (LRRK2) predispose to Parkinson's disease. Consequently, there is much interest in delineating LRRK2 biology, both in terms of gaining further insight into disease causes, and also determining whether or not LRRK2 is a potential Parkinson's disease therapeutic target. Indeed, many potent and selective small molecule inhibitors of LRRK2 have been developed and are currently being used for pre-clinical testing in cell and animal models. In the current study, we have obtained fibroblasts from four subjects with the common LRRK2 mutation, G2019S. Fibroblasts were reprogrammed to induced pluripotent stem cells and then to neural stem cells and ultimately neurons. Two clones for each of the human neural cell lines were then chronically treated with and without either of two distinct inhibitors of LRRK2 and effects on toxicity and Parkinson's disease related phenotypes were assessed. Cells with the G2019S mutation had a propensity to accumulate the pathological Parkinson's disease protein α-synuclein. Moreover, α-synuclein accumulation in the G2019S cells was significantly reduced with both LRRK2 inhibitors in seven of the eight cell lines studied. LRRK2 inhibitors also improved the nuclear morphology of G2019S cells and impacted on measures of autophagy and endoplasmic reticulum stress. Lastly, we did not find evidence of inhibitor toxicity under the chronic treatment conditions. These results add to evidence that LRRK2 inhibitors may have utility in the treatment of Parkinson's disease via reducing α-synuclein.
Insights
LRRK2 inhibitors show promise for Parkinson's disease treatment by reducing toxic alpha-synuclein accumulation in patient-derived neurons. These compounds also improved cellular health without causing toxicity.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Kinase activating mutations in leucine-rich repeat kinase 2 (LRRK2) are a significant genetic risk factor for Parkinson's disease (PD).
- Understanding LRRK2's role is crucial for developing targeted therapies for PD.
- Small molecule LRRK2 inhibitors are available for preclinical testing.
Purpose of the Study:
- To investigate the therapeutic potential of LRRK2 inhibitors in a cellular model of Parkinson's disease.
- To assess the effects of LRRK2 inhibition on alpha-synuclein accumulation and other PD-related phenotypes.
Main Methods:
- Fibroblasts from G2019S mutation carriers were reprogrammed to induced pluripotent stem cells, then neural stem cells, and finally neurons.
- Human neural cell lines were chronically treated with and without two distinct LRRK2 inhibitors.
- Effects on alpha-synuclein levels, nuclear morphology, autophagy, and endoplasmic reticulum stress were evaluated.
Main Results:
- G2019S mutation-carrying cells exhibited alpha-synuclein accumulation, a hallmark of Parkinson's disease.
- LRRK2 inhibitors significantly reduced alpha-synuclein accumulation in most treated cell lines.
- Inhibitors also improved nuclear morphology and modulated autophagy and endoplasmic reticulum stress markers without observed toxicity.
Conclusions:
- LRRK2 inhibitors demonstrate efficacy in reducing pathological alpha-synuclein in a cellular model of LRRK2-associated Parkinson's disease.
- These findings support the potential utility of LRRK2 inhibitors as a therapeutic strategy for Parkinson's disease.
- The study highlights the role of LRRK2 in cellular stress pathways relevant to Parkinson's disease pathogenesis.
More Related Videos
12:49Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
11:31Metabolic Labeling of Leucine Rich Repeat Kinases 1 and 2 with Radioactive Phosphate
Published on: September 18, 2013
